The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

Which strategy should be the global leader in antithrombotic therapy decision making in older patients?

EuroIntervention 2020;15:e1560-e1563. DOI: 10.4244/EIJV15I18A285

1. Cardiology Department, Nimes University Hospital, Montpellier University, ACTION Study Group, Nîmes, France
The benefits of an invasive approach and early revascularisation are well established, and clinical practice guidelines recommend that elderly patients should not be treated differently to younger patients. However, elderly patients are at higher risk of complications and subsequent mortality due to more frequent comorbidities, drug interactions, chronic renal failure, anaemia and frailty1,2. Especially in elderly patients, antiplatelet therapy can be a double-edged sword that reduces the risk of ischaemic events but exposes the patient to an increased risk of major bleeding and subsequent mortality3. As age is a leading factor associated with both ischaemic and bleeding events, the management ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

Chronic total occlusion percutaneous coronary intervention scores: present and future